KRRO
$12.29-0.32 (-2.50%)
Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead produ...
Recent News
Korro Bio, Inc. (KRRO) Reports Q4 Loss, Lags Revenue Estimates
Korro Bio, Inc. (KRRO) delivered earnings and revenue surprises of -175.08% and -13.87%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
United Therapeutics (UTHR) Surges 10.7%: Is This an Indication of Further Gains?
United Therapeutics (UTHR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Collegium Pharmaceutical (COLL) Q4 Earnings and Revenues Miss Estimates
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of -6.99% and -1.53%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
We Think Korro Bio (NASDAQ:KRRO) Needs To Drive Business Growth Carefully
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
H.C. Wainwright Flag KRRO-121 as Independent Value Driver for Korro Bio, Inc. (KRRO)
We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. Korro Bio, Inc. is next on our list of best biotech stocks. TheFly reported on January 29 that H.C. Wainwright upgraded KRRO from Neutral to Buy with a $20 price target. The firm highlighted KRRO-121 as a second, independently […]